RESUMEN
OBJECTIVE: To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. METHODS: Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. RESULTS: Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04-1.17) as the only independent risk factor for a fatal outcome. CONCLUSIONS: This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.
Asunto(s)
COVID-19/fisiopatología , Huésped Inmunocomprometido , Inmunosupresores/administración & dosificación , Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Sistema de Registros , Índice de Severidad de la Enfermedad , Adulto , Factores de Edad , COVID-19/epidemiología , Comorbilidad , Femenino , Humanos , Inmunosupresores/efectos adversos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple Crónica Progresiva/epidemiología , Esclerosis Múltiple Recurrente-Remitente/epidemiología , Neurología , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Sociedades Médicas , EspañaRESUMEN
OBJECTIVE: We report the findings from the Spanish Society of Neurology's NeuroCOVID-19 Registry. METHODS: We performed a multicentre study of patients with neurological manifestations of COVID-19. Participating physicians reported demographic, clinical, and paraclinical data and judged the involvement of COVID-19 in causing neurological symptoms. RESULTS: A total of 233 cases were submitted, including 74 different combinations of manifestations. The most frequently reported were stroke (27%), neuromuscular symptoms (23.6%), altered mental status (23.6%), anosmia (17.6%), headache (12.9%), and seizures (11.6%). The mean age of patients was 61.1 years, with 42.1% being women; a higher proportion of women was recorded among patients with altered mental status, anosmia, and headache. The onset of symptoms differed within categories. Onset of anosmia occurred a mean (standard deviation) of 2.9 (2.5) days after the first general symptom, whereas neuromuscular symptoms appeared after 13.9 (10.1) days. Neurological symptoms were persistent in 33% of patients. General symptoms were present in 97.7% of patients, and results from general laboratory studies were abnormal in 99.4% of patients. Cerebrospinal fluid analysis findings were abnormal in 62.7% of the cases in which this test was performed (n = 51), but positive results for SARS-CoV-2 were only found in one case. CONCLUSIONS: The neurological manifestations of COVID-19 are diverse. Anosmia, myalgia, and headache occur earlier in the course of the disease. Altered mental status, neuromuscular symptoms, and stroke are associated with greater severity. COVID-19 must be incorporated into most clinical and radiological differential diagnoses. COVID-19 may cause persistent and disabling neurological symptoms.
Asunto(s)
COVID-19/complicaciones , Enfermedades del Sistema Nervioso/etiología , SARS-CoV-2 , Adulto , Anciano , Anosmia/epidemiología , Anosmia/etiología , COVID-19/diagnóstico , COVID-19/epidemiología , Prueba de COVID-19 , Enfermedades Cardiovasculares/epidemiología , Causalidad , Comorbilidad , Diabetes Mellitus/epidemiología , Femenino , Cefalea/epidemiología , Cefalea/etiología , Humanos , Masculino , Trastornos Mentales/epidemiología , Trastornos Mentales/etiología , Persona de Mediana Edad , Mialgia/epidemiología , Mialgia/etiología , Enfermedades del Sistema Nervioso/líquido cefalorraquídeo , Enfermedades del Sistema Nervioso/diagnóstico por imagen , Enfermedades del Sistema Nervioso/epidemiología , Neuroimagen , Examen Neurológico , Enfermedades Neuromusculares/epidemiología , Enfermedades Neuromusculares/etiología , Sistema de Registros , SARS-CoV-2/patogenicidad , España/epidemiología , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/etiología , Resultado del Tratamiento , VirulenciaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Historia del Siglo XVI , Historia del Siglo XVII , Enfermedades del Sistema Nervioso/epidemiología , Privación de Sueño/historia , Trastorno de la Conducta del Sueño REM/historia , Enfermedad de Parkinson/historia , Enfermedades por Prión/historia , Neurología/historia , Neurociencias/historiaRESUMEN
INTRODUCCIÓN: El haplotipo HLA-DRB1*1501 es el marcador genético que se ha asociado con un riesgo tres veces mayor de padecer esclerosis múltiple (EM) en caucásicos occidentales. Recientemente se ha sabido que hay una asociación entre el mes de nacimiento en abril, el genotipo HLA-DRB1 y el riesgo de EM en países del norte de Europa y Canadá. Esto apoya la teoría de que debe haber una interacción entre un factor de riesgo estacional con un locus cercano al HLA-DRB1*15 durante la gestación o cerca del posparto. Sujetos y MÉTODOS: Se realizó el genotipado de la presencia y subtipo de HLA-DRB1*1501 en 326 pacientes de dos centros españoles y en 226 controles sin patología neurológica. Se compararon los meses de nacimiento de la muestra de pacientes con los nacimientos mensuales locales en los mismos períodos. RESULTADOS: Comparados los pacientes con EM que eran portadores del alelo HLA-DRB1*15 (10,3%) frente a los pacientes no portadores (3,8%), significativamente más pacientes nacían en diciembre (p = 0,0185). También se confirmaba el mismo mes de nacimiento de diciembre entre sanos portadores frente a no portadores de HLA-DRB1*15 y entre pacientes portadores de HLA-DRB1*15 frente a sanos. CONCLUSIONES: El mes de nacimiento, el genotipo HLA-DRB1*15 y el riesgo de presentar EM están asociados. A diferencia de los resultados obtenidos en países del norte de Europa, donde esta asociación se ha encontrado en el mes de abril, en España es en diciembre. Se demuestra la interacción de un factor de riesgo estacional en invierno en el locus HLA-DRB1*15 o cercano a éste durante la gestación o tras el nacimiento (AU)
INTRODUCTION: A relationship among April births, HLA-DRB1*15:01 genotype and risk of multiple sclerosis (MS) has been described. We aim to determine this association in our cohort of Spanish MS PATIENTS: Subjects and METHODS: We genotyped HLA-DRB1*15:01 allele in 326 MS patients and 226 controls (non-neurological disease patients) by SSP-PCR and compared month of birth with local births during the same period. RESULTS: MS patients carrying HLA-DRB1*15 allele were more frequently born in December (10.3% HLA-DRB1*15+ vs.3.8% HLA-DRB1*15-; p = 0.019). Controls carrying HLA-DRB1*15 allele were less frequently born in December than non-carrier controls (0% HLA-DRB1*15+ vs.10.3% HLA-DRB1*15-; p = 0.028). Thus, December was confirmed as the common month of birth for HLA-DRB1*15-non-carrier controls and MS HLA-DRB1*15-carrier PATIENTS: CONCLUSIONS: Month of birth, HLA-DRB1 genotype and risk of MS are associated. In Spain, this association was found in December, supporting the potential interaction of a seasonal risk factor in winter, inside/close to HLA-DRB1*15 locus, during pregnancy or after birth
Asunto(s)
Humanos , Esclerosis Múltiple/genética , Cadenas HLA-DRB1/genética , Técnicas de Genotipaje/métodos , Estaciones del Año , Factores de Riesgo , Enfermedades Genéticas Congénitas/epidemiología , Estudio ObservacionalRESUMEN
BACKGROUND: This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN ß-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naïve to IFN ß. METHODS: Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and 14.5% were obese. RESULTS: Biomarkers steadily increased during all study period by 45.3% for ß2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment duration. CONCLUSIONS: BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of any AE either.
Asunto(s)
Índice de Masa Corporal , Factores Inmunológicos/efectos adversos , Interferón beta/efectos adversos , Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico , 2',5'-Oligoadenilato Sintetasa/metabolismo , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Masculino , Neopterin/metabolismo , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Resultado del Tratamiento , Microglobulina beta-2/metabolismoRESUMEN
TRAIL and TRAIL Receptor genes have been implicated in Multiple Sclerosis pathology as well as in the response to IFN beta therapy. The objective of our study was to evaluate the association of these genes in relation to the age at disease onset (AAO) and to the clinical response upon IFN beta treatment in Spanish MS patients. We carried out a candidate gene study of TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 and TRAILR-4 genes. A total of 54 SNPs were analysed in 509 MS patients under IFN beta treatment, and an additional cohort of 226 MS patients was used to validate the results. Associations of rs1047275 in TRAILR-2 and rs7011559 in TRAILR-4 genes with AAO under an additive model did not withstand Bonferroni correction. In contrast, patients with the TRAILR-1 rs20576-CC genotype showed a better clinical response to IFN beta therapy compared with patients carrying the A-allele (recessive model: pâ=â8.88×10(-4), pcâ=â0.048, ORâ=â0.30). This SNP resulted in a non synonymous substitution of Glutamic acid to Alanine in position 228 (E228A), a change previously associated with susceptibility to different cancer types and risk of metastases, suggesting a lack of functionality of TRAILR-1. In order to unravel how this amino acid change in TRAILR-1 would affect to death signal, we performed a molecular modelling with both alleles. Neither TRAIL binding sites in the receptor nor the expression levels of TRAILR-1 in peripheral blood mononuclear cell subsets (monocytes, CD4+ and CD8+ T cells) were modified, suggesting that this SNP may be altering the death signal by some other mechanism. These findings show a role for TRAILR-1 gene variations in the clinical outcome of IFN beta therapy that might have relevance as a biomarker to predict the response to IFN beta in MS.
Asunto(s)
Interferón beta/uso terapéutico , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/genética , Polimorfismo de Nucleótido Simple , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF/genética , Adolescente , Adulto , Anciano , Sitios de Unión , Biomarcadores/metabolismo , Femenino , Proteínas Ligadas a GPI/genética , Proteínas Ligadas a GPI/metabolismo , Expresión Génica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Modelos Moleculares , Esclerosis Múltiple/metabolismo , Esclerosis Múltiple/patología , Unión Proteica , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Miembro 10c de Receptores del Factor de Necrosis Tumoral , Ligando Inductor de Apoptosis Relacionado con TNF/genética , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Receptores Señuelo del Factor de Necrosis Tumoral/genética , Receptores Señuelo del Factor de Necrosis Tumoral/metabolismoRESUMEN
The TNF-related apoptosis inducing ligand (TRAIL)/TRAIL receptor system participates in crucial steps in immune cell activation or differentiation. It is able to inhibit proliferation and activation of T cells and to induce apoptosis of neurons and oligodendrocytes, and seems to be implicated in autoimmune diseases. Thus, TRAIL and TRAIL receptor genes are potential candidates for involvement in susceptibility to multiple sclerosis (MS). To test whether single-nucleotide polymorphisms (SNPs) in the human genes encoding TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 and TRAILR-4 are associated with MS susceptibility, we performed a candidate gene case-control study in the Spanish population. 59 SNPs in the TRAIL and TRAIL receptor genes were analysed in 628 MS patients and 660 controls, and validated in an additional cohort of 295 MS patients and 233 controls. Despite none of the SNPs withstood the highly conservative Bonferroni correction, three SNPs showing uncorrected p values<0.05 were successfully replicated: rs4894559 in TRAIL gene, pâ=â9.8×10(-4), ORâ=â1.34; rs4872077, in TRAILR-1 gene, pâ=â0.005, ORâ=â1.72; and rs1001793 in TRAILR-2 gene, pâ=â0.012, ORâ=â0.84. The combination of the alleles G/T/A in these SNPs appears to be associated with a reduced risk of developing MS (pâ=â2.12×10(-5), ORâ=â0.59). These results suggest that genes of the TRAIL/TRAIL receptor system exerts a genetic influence on MS.